nitrendipine has been researched along with Arteriosclerosis in 11 studies
Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antihypertensive and tissue-protective effects of nitrendipine were studied after long-term treatment of rats with experimental hypertension." | 7.68 | Long-term protective effects of nitrendipine in experimental hypertension. ( Kazda, S; Knorr, A; Neuser, D; Seuter, F; Stasch, JP, 1991) |
| "The relationship between the presence of arterial calcinosis and the antihypertensive response to calcium blockers was studied in 40 hypertensive patients with end-stage renal failure (ESRF) on chronic hemodialysis, before and during 16 weeks after administration of nitrendipine in monotherapy." | 5.07 | Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. ( Boussac, I; Delavaux, G; Guerin, AP; London, GM; Marchais, SJ; Metivier, F, 1991) |
| "The relationship between the presence of arterial calcinosis and the antihypertensive response to calcium blockers was studied in 40 hypertensive patients with end-stage renal failure (ESRF) on chronic hemodialysis, before and during 16 weeks after administration of nitrendipine in monotherapy." | 5.07 | Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure. ( Boussac, I; Delavaux, G; Guerin, AP; London, GM; Marchais, SJ; Metivier, F, 1991) |
| " The atherogenic significance of Ca ions and arterial Ca overload was examined under the influence of nicotine, oxidatively modified low-density lipoproteins, spontaneous hypertension, and an elevated extracellular Ca concentration or vitamin D3." | 3.69 | Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations. ( Czirfuzs, A; Fleckenstein-Grün, G; Frey, M; Matyas, S; Thimm, F, 1994) |
| "The antihypertensive and tissue-protective effects of nitrendipine were studied after long-term treatment of rats with experimental hypertension." | 3.68 | Long-term protective effects of nitrendipine in experimental hypertension. ( Kazda, S; Knorr, A; Neuser, D; Seuter, F; Stasch, JP, 1991) |
| "Aortic stiffness and left ventricular hypertrophy (LVH) are predictors of mortality in hemodialysis (HD) patients." | 2.71 | Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. ( Adda, H; Guerin, AP; London, GM; Marchais, SJ; Metivier, F; Pannier, B, 2003) |
| "Nitrendipine (Bayotensin) is a dihydropyridine derivative that appears to preferentially dilate peripheral vessels by a cellular mechanism similar to those found with other calcium blocking agents." | 1.27 | Nitrendipine-stimulated release of prostacyclin-like substance in normal and atherosclerotic animals. ( Basista, E; Basista, M; Grodzińska, L; Ohlrogge, R; Stachura, J; Swies, J; Sławiński, M, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 7 (63.64) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| London, GM | 3 |
| Marchais, SJ | 3 |
| Guerin, AP | 3 |
| Metivier, F | 3 |
| Adda, H | 1 |
| Pannier, B | 1 |
| Fleckenstein-Grün, G | 1 |
| Thimm, F | 1 |
| Czirfuzs, A | 1 |
| Matyas, S | 1 |
| Frey, M | 1 |
| Madsen, JK | 1 |
| Jensen, JW | 1 |
| Sandermann, J | 1 |
| Johannesen, N | 1 |
| Paaske, WP | 1 |
| Egeblad, M | 1 |
| Pedersen, EB | 1 |
| Corsini, A | 1 |
| Accomazzo, MR | 1 |
| Canavesi, M | 1 |
| Sartani, A | 1 |
| Testa, R | 1 |
| Catapano, AL | 1 |
| Fumagalli, R | 1 |
| Paoletti, R | 1 |
| Bernini, F | 1 |
| Matsumura, Y | 1 |
| Hayashi, K | 1 |
| Nayler, WG | 1 |
| Boussac, I | 2 |
| Delavaux, G | 2 |
| Knorr, A | 1 |
| Kazda, S | 1 |
| Neuser, D | 1 |
| Stasch, JP | 1 |
| Seuter, F | 2 |
| Grodzińska, L | 1 |
| Basista, M | 1 |
| Basista, E | 1 |
| Sławiński, M | 1 |
| Swies, J | 1 |
| Stachura, J | 1 |
| Ohlrogge, R | 1 |
1 review available for nitrendipine and Arteriosclerosis
| Article | Year |
|---|---|
Vatanidipine hydrochloride: a new long-lasting antihypertensive agent.
Topics: Animals; Antihypertensive Agents; Arteriosclerosis; Calcium Channel Blockers; Clinical Trials as Top | 2001 |
4 trials available for nitrendipine and Arteriosclerosis
| Article | Year |
|---|---|
Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients.
Topics: Adult; Antihypertensive Agents; Aortic Diseases; Arteriosclerosis; Atenolol; Blood Pressure; C-React | 2003 |
Effect of nitrendipine on renal function and on hormonal parameters after intravascular iopromide.
Topics: Adult; Aged; Aortography; Arteriosclerosis; Calcium Channel Blockers; Contrast Media; Double-Blind M | 1998 |
Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure.
Topics: Adult; Aged; Aging; Aortic Diseases; Arteriosclerosis; Blood Pressure; Calcinosis; Double-Blind Meth | 1991 |
Arteriosclerosis and antihypertensive response to calcium antagonists in end-stage renal failure.
Topics: Administration, Oral; Aged; Analysis of Variance; Arteriosclerosis; Blood Pressure; Calcinosis; Doub | 1991 |
6 other studies available for nitrendipine and Arteriosclerosis
| Article | Year |
|---|---|
Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations.
Topics: Adult; Aged; Aged, 80 and over; Animals; Arteriosclerosis; Calcium; Calcium Channel Blockers; Cells, | 1994 |
The new calcium antagonist lercanidipine and its enantiomers affect major processes of atherogenesis in vitro: is calcium entry involved?
Topics: Animals; Antihypertensive Agents; Arteriosclerosis; Brain; Calcium Channel Blockers; Cell Division; | 1998 |
Calcium, calcium antagonism, atherosclerosis, and ischemia.
Topics: Animals; Arteriosclerosis; Calcium; Coronary Disease; Cytosol; Humans; Hypercholesterolemia; Hyperte | 1992 |
Long-term protective effects of nitrendipine in experimental hypertension.
Topics: Animals; Arteriosclerosis; Atrial Natriuretic Factor; Blood Pressure; Body Weight; Endothelins; Hydr | 1991 |
[Pharmacologic inhibition of experimental atherosclerosis].
Topics: Animals; Arteriosclerosis; Cell Division; Disease Models, Animal; Dose-Response Relationship, Drug; | 1989 |
Nitrendipine-stimulated release of prostacyclin-like substance in normal and atherosclerotic animals.
Topics: Animals; Arteriosclerosis; Cats; Diet; Epoprostenol; Female; Male; Nitrendipine; Platelet Aggregatio | 1987 |